RPRX
Joachim Wernicke - Chief Medical Officer of Repros Therapeutics Inc.

Joachim Wernicke

Chief Medical Officer since 2013

Total compensation: $311,199
Age: 68

Joachim F. Wernicke is Chief Medical Officer of Repros Therapeutics Inc., Dr. Wernicke joined us in 2013 as the Chief Medical Officer and has over 30 years of experience in clinical development and regulatory matters. From 2004 until his in retirement in 2012, Dr. Wernicke was part of the Global Patient Safety group at Eli Lilly and Company, where he was at various times responsible for Cymbalta, Strattera, Zyprexa, Symbyax, and Effient. He was also involved in the development and approval of Strattera and Cymbalta between 1999 and 2004 and clinical development and regulatory matters related to Prozac and other central nervous system drugs between 1984 and 1990. During his career, he has also served as the VP of Clinical and Regulatory Affairs for Cyberonics, Inc. and as a consultant for various pharmaceutical, biotechnology and medical device companies. Dr. Wernicke received a Ph.D. in biochemistry from U.C.L.A. in 1974, and an M.D. from U.C. Irvine in 1979, followed by a child neurology fellowship.

Repros Therapeutics Inc., a biopharmaceutical company, focuses on the development of various drugs to treat hormonal and reproductive system disorders for male and female in the United States. Its product portfolio include Proellex that is in Phase III clinical trials for the treatment of symptoms associated with uterine fibroids, as well as in Phase II clinical trial for the treatment of endometriosis; and enclomiphene, a single isomer of clomiphene citrate, which is in Phase III clinical trials for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. The company was founded in 1987 and is based in The Woodlands, Texas.

  • Repros Therapeutics Inc., 2408 Timberloch Place, The Woodlands 77380, United States
  • reprosrx.com
  • 281-719-3400